Federal Register Notice: FDA has determined the regulatory review period for Novartis’ Exelon (rivastigmine tartrate) is 3,424 days for the extension of a patent which claims that human drug product. Exelon is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. To view this notice, click here.
